AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Inspire Medical: Morgan Stanley maintains a 'Overweight' Rating, The Target Price is $182
ByAinvest
Tuesday, Jul 15, 2025 12:00 pm ET1min read
Morgan Stanley maintains 'Overweight' rating on Inspire Medical(INSP).
The target price is $182, compare with $200 previously.
[Recent Rating]
| Date | Agency | Change | Rating | Rating （previously） | Target Price | Target Price（previously） |
|---|---|---|---|---|---|---|
| 2025-07-15 | Morgan Stanley | Maintains | Overweight | Overweight | $182 | $200 |
[Recent Earning Results] Inspire Medical posted the Q1 of its 2025 financial results on 5/5/2025, reporting total revenue of USD 201.32 million in the first quarter, up 22.75% from USD 164.01 million year over year, reporting net income of USD 2.99 million in the first quarter, compare with USD -10.01 million in the same period last year.
[Company Profile] Inspire Medical Systems, Inc. was incorporated in Delaware in November 2007. The company is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA). The company proprietary Inspire system is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The company have developed a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet